Comparison of Streptococcus pneumoniae serotypes causing acute otitis media & invasive disease in young children in the Czech Republic.

BACKGROUND & OBJECTIVES: The availability of a type-specific pneumococcal vaccine for children is a worldwide problem. It is necessary to study the serotypes prevalent in a country before introducing a type-specific vaccine. The objective of the present study was to analyse the prevalence of Streptococcus pneumoniae serotypes in children suffering from acute otitis media or invasive pneumococcal disease and to compare a coverage of serotypes by individual pneumococcal vaccines. METHODS: Children suffering from acute otitis media and invasive pneumococcal disease were analysed in the Czech Republic from October 1999 to November 2000. Serotyping was performed by the quellung technique using antisera from Statens Serum Institute (Denmark). RESULTS: The most frequent serotypes in patients with acute otitis media were 3, 19F, 23F, 14, 9V, 1, 6B, 11A and 28F. Vaccine coverage for the identified serotypes in acute otitis media patients was 52.1 per cent for the 7-valent vaccine, 57.8 per cent for the 9-valent vaccine and 75.7 per cent for the 11-valent form of the vaccine. In 108 patients with invasive pneumococcal disease, the most frequent serotypes were 6B, 9V, 14, 19F, 3 and 23F. Vaccine coverage for the identified serotypes in patients with invasive pneumococcal disease was 62 per cent for the 7-valent vaccine, 66.4 per cent for the 9-valent vaccine and 77.5 per cent for the 11-valent form of the vaccine. INTERPRETATION & CONCLUSION: Vaccine coverage for the identified serotypes for the 11-valent pneumococcal vaccine was better than the other two vaccines.

Active surveillance of early onset disease due to group B streptococci in newborns.

BACKGROUND & OBJECTIVES: Early onset disease (EOD) due to group B streptococci (GBS) poses a serious threat in many countries. In the Czech Republic neither summarized data on the EOD incidence are available nor a nationwide prevention program has been initiated. The present surveillance was initiated to establish the incidence of EOD due to GBS in newborns in the Czech Republic, distribution of GBS serotypes and GBS susceptibility to antimicrobials. METHODS: Both invasive and carrier GBS isolates from newborns and the data on the newborns' clinical status and maternal colonization and intrapartum prophylaxis were collected from 30 microbiological and clinical centres all over the Czech Republic within prospective active surveillance. HCl extracts of the GBS strains were precipitated with rabbit polysaccharide (I-VIII) and protein (c,R) antisera. RESULTS: Between January 2001 and September 2002, GBS isolates from 239 full-term and 46 preterm newborns were collected. Of the 285 GBS positive newborns, 105 had invasive EOD, 42 showed suspected EOD, and in 56 clinical diagnosis was not specified. Eighty two GBS isolates were obtained from healthy colonized infants. The isolates obtained from newborns with confirmed invasive EOD were mostly of serotype III (42%), followed by serotypes V a Ia (13% each). Types Ia (26%), III (22%) and II (20%) were most frequent among the isolates from colonized individuals. Protein antigens (c protein, R protein) either coupled with polysaccharide or alone were found in 70 per cent (30 and 40 %, respectively) of the study isolates. INTERPRETATION & CONCLUSION: The incidence of EOD due to GBS found in the Czech Republic 0.7-1.0 per 1000 live births was comparable with the rates reported in the countries where the prevention programme has been implemented nationwide. Serotypes III, V and Ia prevailing among the isolates from Czech newborns with EOD belonged to those most frequently identified in the USA and Western European countries.

Screening of the most common medium-chain acyl CoA dehydrogenase (MCAD) deficiency mutation (K329E) in the Czech newborn population.

Medium chain acyl-CoA dehydrogenase (MCAD) deficiency is the commonest inherited disorder of fatty acid oxidation. Most clinically ascertained cases are caused by thc point mutation K329E in MCAD gene. The frequency of this mutation as determined by usc of dried blood spots on Guthrie cards and the PCR NeoI digestion method. Using molecular ncwborn screening we found no K329E homozygote and 14 K329E heterozygotes in 2,826 newborns from Moravian area of the Czech Republic. Lower frequency of K329E carriers (1/202)) suggests that the incidence of MCAD deficiency will be probably lower in our population than we expected.